News of Note—GeoVax, Inovio, BiondVax and more

newspaper
In this week's news of note, GeoVax named a new CEO. (Pixabay)

Here is some other vaccine news of note for the week:

> GeoVax announced that its president and CEO Robert McNally is retiring at the end of the month, and that industry veteran David Dodd will take the role effective Sept. 1. McNally will remain on the company's board. Release

> Inovio Pharmaceuticals kicked off a phase 1/2 study of a therapeutic HIV vaccine called Pennvax-GP. Release

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> Investigators have enrolled the first patient in a phase 3 trial of BiondVax's universal flu vaccine candidate. Release

> A study published in Pediatrics found that children of mothers who received a prenatal Tdap vaccination were not more likely to be born with autism. Washington Post article

Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.